Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway

Activating mutations in RAS are present in ~ 30% of human tumors, and the resulting aberrations in ERK/MAPK signaling play a central role in oncogenesis. However, the form of these signaling changes is uncertain, with activating RAS mutants linked to both increased and decreased ERK activation in vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillies, Taryn E, Pargett, Michael, Silva, Jillian M, Teragawa, Carolyn K, McCormick, Frank, Albeck, John G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569415/
https://www.ncbi.nlm.nih.gov/pubmed/33073539
http://dx.doi.org/10.15252/msb.20209518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569415/
https://www.ncbi.nlm.nih.gov/pubmed/33073539
http://dx.doi.org/10.15252/msb.20209518

Ejemplares similares